Cytosorbents Corporation

Equities

CTSO

US23283X2062

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
1.1 ^USD	-1.79%		+11.12%	-0.90%

05/07	Cytosorbents Corporation and Cytosorbents Medical, Inc. Enter Loan and Security Agreement	CI
28/06	Cytosorbents Corporation announced that it expects to receive $20 million in funding	CI

CytoSorbents : Appoints David D. Cox, PhD, MBA as Vice President – Global Regulatory Affairs

January 22, 2021 at 04:46 am IST

Cytosorbents Contact:
Amy Vogel

Investor Relations

732-398-5394

avogel@cytosorbents.com

Investor Relations Contact:

Jeremy Feffer

LifeSci Advisors

917-749-1494

jeremy@lifesciadvisors.com

Public Relations Contact:

Eric Kim

Rubenstein Public Relations

212-805-3055

ekim@rubensteinpr.com

Attachments

Original document
Permalink

Disclaimer

CytoSorbents Corporation published this content on 21 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 January 2021 23:15:01 UTC

Latest news about Cytosorbents Corporation

Cytosorbents Corporation and Cytosorbents Medical, Inc. Enter Loan and Security Agreement	05/07	CI
Cytosorbents Corporation announced that it expects to receive $20 million in funding	28/06	CI
CytoSorbents' Blood Purification Device Gets Approval in Taiwan	24/06	MT
CytoSorbents Corporation Announces Regulatory Approval of CytoSorb® in Taiwan	24/06	CI
Cytosorbents Corporation Announces the Launch and Immediate Availability of the PuriFi Blood Pump in the European Union	13/06	CI
Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M	10/05	MT
Transcript : Cytosorbents Corporation, Q1 2024 Earnings Call, May 09, 2024	10/05
Cytosorbents Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Transcript : Cytosorbents Corporation - Analyst/Investor Day	06/05
Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M	15/03	MT
Transcript : Cytosorbents Corporation, Q4 2023 Earnings Call, Mar 14, 2024	15/03
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure	17/01	CI
North American Morning Briefing : Stock Futures Struggle After Weak China Data	02/01	DJ
HC Wainwright Downgrades Cytosorbents to Neutral From Buy, Cuts Price Target to $1 From $5.50	29/12	MT
S&P 500 ekes out meager gains, flirts with bull market confirmation	29/12	RE
Sector Update: Health Care Stocks Rise in Late Afternoon	29/12	MT
Top Midday Decliners	29/12	MT
Wall St inches higher as S&P 500 flirts with bull market confirmation	29/12	RE
US Stocks Holding on for Small Thursday Gains, Again Drifting Near Record Highs	29/12	MT
US Stocks Adding to Recent Gain Amid New Economic Data	28/12	MT
B. Riley Trims Price Target on Cytosorbents to $3 From $4, Maintains Buy Rating	28/12	MT
US STOCKS -Wall Street edges higher as year end approaches, rate cuts in focus	28/12	RE
Sector Update: Health Care Stocks Steady Premarket Thursday	28/12	MT
Sector Update: Health Care	28/12	MT

Chart Cytosorbents Corporation

Duration

Period

More charts

Company Profile

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Companyâs flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.

Sector

Advanced Medical Equipment & Technology

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cytosorbents Corporation

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.1 USD

Average target price

2.667 USD

Spread / Average Target

+142.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
CYTOSORBENTS CORPORATION	-0.90%	5.97Cr
THERMO FISHER SCIENTIFIC	+4.57%	21TCr
DANAHER CORPORATION	+8.61%	19TCr
INTUITIVE SURGICAL, INC.	+26.34%	15TCr
BOSTON SCIENTIFIC CORPORATION	+33.90%	11TCr
SIEMENS HEALTHINEERS AG	+3.88%	6.56TCr
EDWARDS LIFESCIENCES CORPORATION	+14.50%	5.26TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	4.68TCr
AGILENT TECHNOLOGIES, INC.	-3.98%	3.9TCr
GE HEALTHCARE TECHNOLOGIES INC.	+6.66%	3.76TCr

Other Advanced Medical Equipment & Technology